Association of aromatase inhibitors with coronary heart disease in women with early breast cancer

Cancer Investigation

Volumn 32, Issue 4, 2014, Pages 99-104

  Seruga, B ^a   Zadnik, V ^a   Kuhar, C Grasic ^a   Marinko, T ^a   Cufer, T ^b   Zakotnik, B ^a   Zorman, D ^c   Ocana, A ^d   Amir, E ^e  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Angiography; Aromatase inhibitor; Coronary artery disease

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAMOXIFEN; TIME FACTORS;

EID: 84898749292     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357907.2014.880452     Document Type: Article

References (25)

1. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R. Meta-Analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509-518.
2. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy forwomenwith hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784-3796.
3. Chlebowski RT. Clinical trial presentations, agency guidelines, and oncology practice: Findings from the arimidex, tamoxifen, alone or in combination trial. Clin Breast Cancer 2008;8:343-346.
4. Lüftner D, Scheller J, Kölm P, Possinger K. Prescription pattern of aromatase inhibitors for the adjuvant therapy of breast cancer in Germany - results of the second survey among gynaecologists and medical oncologists. Onkologie 2008;31:19-25.
5. Svahn TH, Niland JC, Carlson RW, Ottesen RA, Theriault LR, Edge SB, Schott AF, BookmanMA, Weeks JC. Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer. J Natl Compr Canc Netw 2009;7:115-121.
6. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-Analysis. J Natl Cancer Inst 2011;103:1299-1309.
7. Node K, Kitakaze M, Kosaka H, Minamino T, Funaya T, Hori M. Amelioration of ischemia- And reperfusion-induced myocardial injury by 17beta-estradiol: Role of nitric oxide and calciumactivated potassium channels. Circulation 1997;96:1953-1963.
8. Widder J, Pelzer T, von Poser-Klein C, Hu K, Jazbutyte V, Fritzemeier KH, Hegele-Hartung, Neyses L, Bauersachs J. Improvement of endothelial dysfunction by selective estrogen receptor-Alpha stimulation in ovariectomized SHR. Hypertension 2003;42:991-996.
9. Jazbutyte V, Stumpner J, Redel A, Lorenzen JM, Roewer N, Thum T, Kehl F. Aromatase inhibition attenuates desfluraneinduced preconditioning against acute myocardial infarction in male mouse heart in vivo. PLoS One 2012;7:e42032.
10. Drugs@FDA. FDA approved drug products. Arimidex. http:// www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuse action=Search.Label ApprovalHistory#labelinfo (accessed October 8, 2012).
11. Ligibel JA, James O'Malley A, Fisher M, Daniel GW, Winer EP, KeatingNL. Risk ofmyocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Breast Cancer Res Treat 2012;131:589-597.
12. Harrell FE. Regression Modeling Strategies:With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer-Verlag, 2001.
13. Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzik J. Influence of comorbidities and age on risk of death without recurrence: A retrospective analysis of the arimidex, tamoxifen alone or in combination trial. J Clin Oncol 2011;29:4266-4272.
14. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study. Breast Cancer Res 2011;13:R64.
15. Nabel EG, Braunwald E. A tale of coronary artery disease andmyocardial infarction. N Engl J Med 2012;366(1):54-63.
16. Hoenig MR, Doust JA, Aroney CN, Scott IA. Early invasive versus conservative strategies for unstable angina and non-ST-elevation myocardial infarction in the stent era. Cochrane Database Syst Rev 2006;19(3):CD004815.
17. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, Feyzi J, DeMets DL. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991;115:860-864.
18. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. (The Scottish Cancer Trials Breast Group.) BMJ 1995;311:977-980.
19. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997;89:776-782.
20. Nordenskjöld B, Rosell J, Rutqvist LE, Malmstrom PO, Bergh J, Bengtsson NO, Hatschek T, Wallgren A, Carstensen J. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial. J Natl Cancer Inst 2005;97:1609-1610.
21. Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, Baum M. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 2011;29:1657-1663.
22. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-Analysis of randomised trials. Lancet 2011;378(9793):771-784.
23. Collins P, Mosca L, GeigerMJ, GradyD, Kornitzer M, Amewou- Atisso MG, Effron MB, Dowsett SA, Barrett-Connor E, Wenger NK. Effects of the selective estrogen receptormodulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: Results of subgroup analyses by age and other factors. Circulation 2009;119:922-930.
24. Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M. Cardiovascular effects of tamoxifen in women with and without heart disease: Breast cancer prevention trial. (National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators) J Natl Cancer Inst 2001;93: 16-21.
25. Goss PE, Ingle JN, Alés-Mart?́nez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Sarto GE, GArber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Richardson H. NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364: 2381-2391.